Heparin Plus a Glycoprotein IIb/IIIa Inhibitor Versus Bivalirudin Monotherapy and Paclitaxel-Eluting Stents Versus Bare-Metal Stents in Acute Myocardial Infarction (HORIZONS-AMI): Final 3-Year Results From a Multicentre, Randomised Controlled Trial

Study Questions:

What are the 3-year outcomes for patients randomly allocated to the different pharmacological and stent-type groups in the HORIZONS-AMI trial?